LightLab Imaging Returns to EuroPCR 2010 With Strong and Growing Worldwide Acceptance of C7-XR OCT Imaging System

PARIS, May 21 /PRNewswire/ -- LightLab Imaging, Inc., the pioneer and leader in the development of Optical Coherence Tomography (OCT) technology for coronary and other imaging applications will showcase its C7-XR™ Imaging System and its companion C7 Dragonfly™ Imaging Catheter at EuroPCR 2010 in Paris, France on May 25 to 28, at booth M-12.

It was at last year's EuroPCR that the C7-XR Imaging System was introduced.   In the year since its introduction, thousands of imaging procedures have been performed throughout the European Union by the many centers that have incorporated the imaging capabilities of the LightLab system into their practice.

"One year after the launch of our C7-XR system at PCR, the results throughout Europe have been outstanding," said David Kolstad, CEO of LightLab Imaging. "This has been a tremendous year for LightLab OCT both in Europe and in the United States, with the achievement of our FDA clearance and US introduction earlier this month. We are pleased with our progress toward LightLab OCT becoming the worldwide intracoronary imaging gold-standard."

At this year's PCR, LightLab will raise the intracoronary imaging standard even higher with its preview of 3D OCT – an advanced capability that will allow clinicians to view the entire pullback length as a 3D image. This imaging advancement creates a dynamic multidimensional view of the coronary anatomy, and is designed to further expand both the information provided and the daily clinical value of LightLab OCT solutions.

LightLab will host a luncheon symposium on Wednesday, May 26, from 12:00pm - 1:30pm, Room 251, entitled 'OCT in the real world: Today's clinical applications.' This session will be chaired by Francesco Prati, MD and Fernando Alfonso, MD. Case presentations will be made by Lutz Bullesfeld, MD, Fernando Alfonso, MD, Juan Granada, MD, Robert Whitbourn, MD, and Tom Adriaenssens, MD. This informative session will share clinically relevant optical coherence tomography applications, teach techniques for improving image quality, and discuss what further research is required to expand indications.

This year's EuroPCR features several sessions focusing almost entirely on OCT and several other presentations that include OCT topics, all demonstrating the role that OCT can play in coronary interventions. Those sessions are:

EuroPCR, the leading international course dedicated to the cardiovascular community, is being held in Paris, France from May 25 to 28, 2010. In addition to presentations, it will also include live cases; several of these are expected to feature the use of LightLab OCT and demonstrate its clinical utility. EuroPCR Delegates from Europe and other continents will share experience and compare the approaches and practices from their respective countries.

St. Jude Medical, Inc., a global medical device company, and LightLab recently announced a definitive agreement under which St. Jude Medical will acquire LightLab for approximately $90 million in cash. The transaction is expected to close by the end of the second quarter, subject to customary closing conditions and regulatory approvals.

About LightLab Imaging, Inc.

LightLab Imaging, Inc., based in Westford MA, is the world's leading manufacturer and marketer of Optical Coherence Tomography (OCT) for vascular and other imaging applications. LightLab's OCT systems and imaging catheters are cleared for sale in 40 countries in Europe, Asia, the Middle East and North and South America. The company was founded in 1998 by the inventors of OCT, and has exclusive license to a broad range of OCT technologies and applications from MIT and other entities. The LightLab mission is to develop and distribute photonic imaging technologies that improve patients' wellbeing, enhance diagnostic medicine, improve outcomes, and reduce healthcare expenditures. With the ability to resolve real-time images to 15 micrometers, the LightLab Imaging OCT Imaging Systems offer physicians more precise information than ever before. For more information, visit www.lightlabimaging.com.

About LightLab OCT

LightLab Optical Coherence Tomography (OCT) is the Extreme Resolution™ imaging technology for cardiovascular disease diagnosis. LightLab OCT utilizes near-infrared light to create images with 10 times the resolution of Intravascular ultrasound (IVUS). The proprietary LightLab OCT interferometer analyzes reflected light waves to create our extreme resolution Golden Image™ for enhanced diagnosis and treatment decisions.

The bandwidths of infrared light utilized for OCT are far higher than ultrasound, resulting in greatly increased image resolution. In fact, LightLab OCT provides intravascular images with 15 micrometers axial resolution, about twice the size of a red blood cell. Despite providing this extreme resolution LightLab OCT is a radiation-free* imaging medium.

*OCT is not a source of ionizing radiation, such as X-rays.

SOURCE LightLab Imaging, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED